

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
IN RE APPLICATION OF: Mark B. Chidlaw, et al. :  
Examiner: To Be Assigned  
APPLICATION NO.: To Be Assigned :  
FILING DATE: Herewith :Group Art Unit: To Be Assigned  
TITLE: Controlled-Release of an Active Substance Into a :  
High Fat Environment  
-----  
Mail Stop Patent Applications  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: DECEMBER 3, 2003

James T. Jones  
James T. Jones  
Attorney for Applicant(s)  
Reg. No. 30,561

Pfizer Inc.  
Patent Department, Box 8260-1611  
Eastern Point Road  
Groton, CT 06340  
(860) 441-4903

**EXPRESS MAIL NO. EU 271824686US**

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i> Page 1 of 1									<b>ATTY. DOCKET NO. PC9858A</b>			<b>SERIAL NO. To Be Assigned</b>		
<b>APPLICANT</b> Mark B. Chidlaw, et al.									<b>FILING DATE</b> Herewith			<b>GROUP To Be Assigned</b>		

  

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	US	5	6	1	6	3	4	5	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	5	6	1	6	3	4	5	1 April 97	Geoghegan et al	424	497	
	US	5	6	3	7	3	2	0	10 June 97	Bourke et al	424	489	
	US	5	5	0	5	9	6	2	9 April 96	Sparks	424	473	
	US	5	3	5	4	5	5	6	11 Oct 94	Sparks et al	424	419	
	US	5	5	6	7	4	4	1	22 Oct 96	Chen	424	494	
	US	5	7	2	8	4	0	2	17 March 98	Chen et al	424	481	
	US	5	4	5	8	8	8	7	17 Oct 95	Chen et al	424	464	
	US	5	7	3	6	1	5	9	7 April 98	Chen et al	424	480	
	US	4	8	0	1	4	6	1	31 Jan 89	Hamel et al	424	467	
	US	5	7	1	8	7	0	0	17 Feb 98	Edgren et al	604	892.1	
	US	5	5	4	0	9	1	2	30 July 96	Roorda et al	424	422	
	US	5	6	1	2	0	5	9	18 March 97	Cardinal et al	424	495	
	US	5	6	9	8	2	2	0	16 Dec 97	Cardinal et al	424	451	
	US	4	2	8	5	9	8	7	25 Aug 81	Ayer et al	427	3	
	US	4	2	0	3	4	3	9	20 May 80	Theeuwes	128	260	
	US	4	1	1	6	2	4	1	26 Sept 78	Theeuwes et al	128	260	
	US	4	7	8	3	3	3	7	8 Nov 88	Wong et al	424	468	
	US	4	7	6	5	9	8	9	23 Aug 88	Wong et al	424	473	
	US	5	4	1	3	5	7	2	9 May 95	Wong et al	604	892	
	US	5	3	2	4	2	8	0	28 June 94	Wong et al	604	892	
	US	4	8	5	1	2	2	8	25 July 89	Zentner et al	424	456	
	US	4	9	6	8	5	0	7	6 Nov 90	Zentner et al	424	465	
	US	5	3	6	6	7	3	8	22 Nov 94	Rork et al	424	473	

  

FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO

  

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
		Isaac Ghebre-Sellassie, Neth. Appl., 10 pp, 1991 (with English translation)											
		D. S. Sheorey, et al., J. Microencapsulation, 8 (3), 359-68, 1991											
		A. Kristi, et al., Drug Dev. Ind. Pharm., 17(8), pgs 1109-1130, 1991											
		Shun Por Li, et al., Pharm. Technol. 14(3), 20, 22-24, 1990											
		D. K. Pollock, et al., Pharm. Technol. Eur. 9(1), pgs 26-36, 1997											

  

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>

  

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL NO. 920271824686 US

4/97, !disclos, 1/1